All In Biotech

NDA 012151 · Pfizer

Aldactone

Spironolactone · Oral · Aldosterone Antagonist

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1960

Jan 21, 1960

Approved uses

2

Original approval plus efficacy supplements

Registered trials

286

52 Phase 3, 28 recruiting

FAERS reports

142,744

111,491 serious, 18,312 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 30, 1981 Supplement 30 · Efficacy
  • Jan 21, 1960 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • ALDACTONE · SPIRONOLACTONE 25MG · TABLET, ORAL · Prescription · TE AB
  • ALDACTONE · SPIRONOLACTONE 50MG · TABLET, ORAL · Prescription · TE AB
  • ALDACTONE · SPIRONOLACTONE 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Spironolactone" as an intervention, any sponsor and status, largest first.

All 286 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea11,078
  • fatigue8,762
  • nausea8,345
  • diarrhoea8,003
  • acute kidney injury7,153
  • dizziness6,673
  • headache6,414
  • hypotension6,175
  • off label use6,086
  • drug ineffective5,550
  • fall5,362
  • asthenia5,282

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,611
20051,925
20061,911
20071,861
20082,088
20092,528
20103,341
20113,581
20124,304
20133,937
20145,469
20157,144
20168,776
20178,042
20189,684
20199,988
20209,246
20218,774
20228,916
20239,822
202410,781
202510,709
20268,302

Recalls

1 FDA enforcement reports for this application.

  • Sep 4, 2013 · Class II · Terminated

    Marketed without an Approved NDA/ANDA: This recall is being initiated because of changes to the dissolution profile in distributed lots resulting from a manufacturing site change. There is currently no approved...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aldactone (Spironolactone)

2024 spending

$429K

Beneficiaries

469

1,291 claims

Per beneficiary

$914

$3.66 per unit

View as table
YearSpending
2020$591,299
2021$624,111
2022$535,855
2023$545,668
2024$428,587

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,075 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.